20 results found.

Transfusional Iron Overload, Thalassemia Major, Sickle Cell Disea Clinical Trial using Hepatic biomagnetic susceptibility measurement

Columbia University - Recruiting 5 years to 80 years.
- High-Tc Susceptometer to Monitor Transfusional Iron Overload (NSR Device).
Hepatic biomagnetic susceptibility measurement

Genotype, Pain, Sickle Cell Anemia, or Vaso-Occlusive Pain Crisis Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Exploratory Studies of Psychophysical Pain Phenotyping and Genetic Variability in Sickle Cell Disease.

Healthy, or Sickle Cell Anemia Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 45 years.
- Collection and Storage of Umbilical Cord Hematopoietic Stem Cells for Sickle Cell Disease Therapy.

Pulmonary Hypertension, or Sickle Cell Anemia Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Determining the Prevalence and Prognosis of Secondary Pulmonary Hypertension in Adult Patients With Sickle Cell Anemia.

Congenital Hemolytic Anemia, or Diamond-Blackfan Anemia Clinical Trial using Radiotherapy; Alemtuzumab (Campath ); Sirolimus (Rapamune )

National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 65 years.
- Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation For Severe Congenital Anemias Including Sickle Cell Disease, Thalassemia, and Diamond Blackfan Anemia.
Radiotherapy; Alemtuzumab (Campath ); Sirolimus (Rapamune )

Anemia, Sickle Cell Clinical Trial using systematic psychological care

Fondation Ophtalmologique Adolphe de Rothschild - Recruiting N/A to 18 years.
- The Impact of Systematic Psychological and Medical Care for Treatment of Pediatric Patients With SCD: : A Luxury or a Necessity?.
systematic psychological care

Peripheral Blood Stem Cell Transplantation, Anemia, Sickle Cell, Clinical Trial using PBMC Transplant; Alemtuzumab (Campath ); Sirolimus (Rapamune ); Cyclophosphamide (Cytoxan ); Low Dose Irradiation

National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older.
- Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-Thalassemia.
PBMC Transplant; Alemtuzumab (Campath ); Sirolimus (Rapamune ); Cyclophosphamide (Cytoxan ); Low Dose Irradiation

Sickle Cell Anemia, Sickle Cell-hemoglobin C Disease, or Sickle C Clinical Trial using Fludarabine; Cytarabine; Cellular Infusions; Total Body Irradiation; Cyclophosphamide; Bortezomib; Rituximab; Plasmapheresis

Thomas Jefferson University - Recruiting 18 years to 45 years.
- Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Sickle Cell Anemia From HLA Matched or Partially-Matched Related Donors.
Fludarabine; Cytarabine; Cellular Infusions; Total Body Irradiation; Cyclophosphamide; Bortezomib; Rituximab; Plasmapheresis

Sickle Cell Disease Clinical Trial using Alemtuzumab; Fludarabine; Melphalan

Hackensack University Medical Center - Recruiting 2 years to 30 years.
- Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 Years Old.
Alemtuzumab; Fludarabine; Melphalan

Hemoglobin SC Disease, Hematologic Diseases, Sickle Cell Anemia, Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 5 years or older.
- Studies of the Natural History of Sickle Cell Disease and Other Hemolytic Disorders.

Sickle Cell Disease, Sickle Cell Anemia, or Anemia, Sickle Cell Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- End-Alveolar Carbon Monoxide as a Measure of Erythrocyte Survival and Hemolytic Severity in Sickle Cell Disease.

Sickle Cell Anemia Clinical Trial

St. Jude Children's Research Hospital - Recruiting 5 years to 19 years.
- State Of The Art Functional Imaging In Sickle Cell Disease.

Sickle Cell Disease Clinical Trial using G-CSF; cyclophosphamide; fludarabine phosphate; mycophenolate mofetil; Sirolimus; Allogeneic bone marrow transplantation; total-body irradiation; Levetiracetam

Sidney Kimmel Comprehensive Cancer Center - Recruiting 2 years to 70 years.
- A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients With Sickle Cell Anemia and Other Hemoglobinopathies.
G-CSF; cyclophosphamide; fludarabine phosphate; mycophenolate mofetil; Sirolimus; Allogeneic bone marrow transplantation; total-body irradiation; Levetiracetam

Sickle Cell Anemia Clinical Trial using Measurement of carbon monoxide level in exhaled breath

Children's Hospital & Research Center Oakland - Recruiting 5 years to 14 years.
- Phase 1 Study of Carbon Monoxide Monitor for the Measurement of End-Tidal Carbon Monoxide Levels in Children With or Without Hemolysis.
Measurement of carbon monoxide level in exhaled breath

Sickle Cell Anemia Clinical Trial using Regadenoson; Regadenoson Placebo

Dana-Farber Cancer Institute - Recruiting 18 years to 70 years.
- A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia.
Regadenoson; Regadenoson Placebo

Thalassemia, or Sickle Cell Disease Clinical Trial using Medical Chart Summary

HaEmek Medical Center, Israel - Recruiting 5 years to 45 years.
- Iron Overload and Growth Velocity in Thalassemia and Sickle Cell Anemia.
Medical Chart Summary

Anemia, Sickle Cell, or Pain Clinical Trial using Fentanyl Citrate; Normal Saline

Montefiore Medical Center - Recruiting 3 years to 21 years.
- Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis: A Randomized, Double Blind Placebo Controlled Trial.
Fentanyl Citrate; Normal Saline

Sickle Cell Disease, or Sickle Cell Anemia Clinical Trial using regadenoson infusion with contrast-enhanced ultrasound; contrast-enhanced ultrasound

Blood Center of Wisconsin - Recruiting 18 years to 70 years.
- Effect of Adenosine 2A Receptor Agonist Regadenoson on Microvascular Blood Flow in Sickle Cell Anemia.
regadenoson infusion with contrast-enhanced ultrasound; contrast-enhanced ultrasound

Sickle Cell Disease Clinical Trial

Children's Hospital Los Angeles - Recruiting 13 years or older.
- Iron-mediated Vascular Disease in Sickle Cell Disease..

Anemia, Sickle Cell, or Transfusion Hemochromatosis Clinical Trial using deferasirox

Children's Hospital Los Angeles - Recruiting 14 years or older.
- Clinical Importance of Treating Iron Overload in Sickle Cell Disease.
deferasirox